SYNLOGIC, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SYNLOGIC, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-12-31 was $0.00.
- SYNLOGIC, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was -$1.00K.
- SYNLOGIC, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $149.00K.
- SYNLOGIC, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $4.00K.
- SYNLOGIC, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $152.00K, a 15100.00% increase from fiscal 2023.
- SYNLOGIC, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $1.00K, a 98.36% decline from fiscal 2022.
- SYNLOGIC, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $61.00K, a 78.21% decline from fiscal 2021.
- SYNLOGIC, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $280.00K, a 1650.00% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $152.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | |
| 2024-06-30 | $149.00K 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $4.00K 10-Q · filed 2025-05-08 | |
| 2023-12-31 | $1.00K 10-K · filed 2025-03-06 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $61.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $68.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $9.00K 10-Q · filed 2023-08-10 | $277.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $52.00K 10-Q · filed 2023-05-11 | $332.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $280.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $209.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $64.00K 10-Q · filed 2022-08-11 | |
| 2020-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $16.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $1.00K 10-Q · filed 2021-11-10 | |
| 2018-12-31 | $141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $244.00K 10-K · filed 2020-03-12 |
| 2018-09-30 | $103.00K 10-Q · filed 2019-11-12 | |
| 2017-12-31 | $5.00K 10-K · filed 2019-03-12 | |
| 2016-12-31 | $9.00K 10-K · filed 2017-03-15 | |
| 2015-12-31 | $67.00K 10-K · filed 2017-03-15 | |
| 2014-12-31 | $209.00K 10-K · filed 2017-03-15 | |
| 2013-12-31 | $1.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |